Hunter Shkolnik Quoted in Healthline Regarding Plavix Lawsuit
September 13, 2016 | Pharmaceutical Litigation
As was recently reported, the California Supreme Court ruled that eight Plavix product liability lawsuits against manufacturer Bristol-Myers Squibb and distributor McKesseon Corporation can proceed in San Francisco Superior Court.
Plavix (clopidogrel) is a blood thinner used to reduce the risk of blood clots and is prescribed to people who are at a higher risk of cardiovascular problems such as heart attacks or strokes. However, the lawsuits allege that Plavix causes excessive bleeding, brain injuries and even death. In fact, Hunter Shkolnik says that Plavix was ineffective in about 25% of the plaintiffs and for others it was no more effective than aspirin.
“For the vast majority there was no reason to take this drug (Plavix)”
In addition, Hunter says that Bristol-Myers Squibb was aware of some of the potential health risks associated with Plavix, that the company was “overly aggressive in marketing the drug” to consumers and physicians.
This is not the first brush with controversy over Plavix’s effectiveness. The New England Journal of Medicine published several studies indicating that Plavix users had a higher rate of ulcers than people who took aspirin combined with a heartburn pill. The FDA published an advisory regarding the effectiveness of Plavix in 2009 and, in 2010, issued a “black box” warning for Plavix on its reduced effectiveness for certain patients.
How Can We Help?
Do you need assistance with a legal matter? Our attorneys have the experience needed to guide you in the right direction.